scholarly journals Willingness to pay for innovation: the case of the anti-HCV drugs from the Italian National Health Service perspective

2015 ◽  
Vol 2 (2) ◽  
pp. GRHTA.5000201 ◽  
Author(s):  
Francesco Saverio Mennini ◽  
Andrea Marcellusi ◽  
Raffaella Viti ◽  
Massimo Andreoni
Keyword(s):  
National Health Service ◽  
Health Service ◽  
Willingness To Pay ◽  
National Health ◽  
Italian National Health Service ◽  
Italian National Health ◽  
Service Perspective ◽  
Health Service Perspective

scholarly journals The effects of disease cross-coverage by dupilumab on the costs sustained by the Italian National Health Service

2020 ◽  
Vol 7 (1) ◽  
pp. 33-39
Author(s):  
Claudio Jommi ◽  
Filippo Cipriani ◽  
Francesca Fanelli ◽  
Maria Paola Pedone ◽  
Walter Canonica
Keyword(s):  
National Health Service ◽  
Health Service ◽  
National Health ◽  
Economic Benefit ◽  
Severe Atopic Dermatitis ◽  
Crowding Out ◽  
Alternative Treatments ◽  
Published Evidence ◽  
Italian National Health Service ◽  
Italian National Health

Background and research question: Label extension for treatments and the relevant disease cross-coverage may produce an economic benefit. This paper assesses this benefit for dupilumab in the perspective of the Italian National Health Service. Dupilumab was approved for reimbursement for severe atopic dermatitis (AD), severe and refractory asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The analysis focused on the crowding-out effect of dupilumab on alternative treatments. Methods: The research relied on a simplified budget impact model. The model was populated by data from published evidence and relied on three alternative scenarios for market penetration (15%-30%-100%). Results: Avoidable direct health annual costs due to cross-coverage for (i) asthma in patients treated for AD ranged from 0.46 to 3.43 million euros, (ii) asthma in patients treated for CRSwNP ranged from 0.08 to 0.88 million euros, (iii) CRSwNP in patients treated for asthma ranged from 0.41 to 4.05 million euros respectively. The total economic benefit ranges from 0.95 to 8.36 million euros. Discussion: The research estimated the crowding-out effect of dupilumab on alternative treatments. It did not incorporate avoided/incremental events due to a possible better/worse risk-benefit profile of dupilumab vs alternative treatments and the economic benefit of cross-coverage on lower diseases severity (for example mild asthma). Nonetheless, the analysis relies on the best available evidence for Italy to shed light on a topic which has not been sufficiently investigated, and provides data that will be potentially very important for policy-makers, payers and those who manage new treatments.

scholarly journals Sustainability of the Italian National Health Service

2018 ◽  
Vol 28 (suppl_4) ◽  
Author(s):  
F Madotto ◽  
LG Mantovani ◽  
MA Riva ◽  
C Fornari ◽  
PA Cortesi ◽  
...  
Keyword(s):  
National Health Service ◽  
Health Service ◽  
National Health ◽  
Italian National Health Service ◽  
Italian National Health
Sign in / Sign up

Export Citation Format

Share Document